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HR

:   hazard ratio

RV

:   right ventricle

RVSD

:   right ventricular systolic dysfunction

RVSF

:   right ventricular systolic function

TAPSE

:   tricuspid annular plane systolic excursion

TAVR

:   transcatheter aortic valve replacement

TR

:   tricuspid regurgitation

Clinical PerspectiveWhat Is New?This study adds to the evolving discussion of right ventricular systolic dysfunction as a prognostic marker for transcatheter aortic valve replacement, not only because of its large sample size but also its discovery of severe tricuspid regurgitation and right ventricular dilation as markers for adverse prognosis.In patients with severe symptomatic aortic stenosis who undergo transcatheter aortic valve replacement, the presence of right ventricular systolic dysfunction, severe tricuspid regurgitation, and right ventricular dilation all portend increased risk of adverse outcomes.What Are the Clinical Implications?Clinicians should consider meticulous preoperative assessment of right ventricular systolic dysfunction, including evaluation of tricuspid regurgitation and right ventricular dilation in transcatheter aortic valve replacement candidates, and also strive for optimization of right ventricular function to improve outcomes.

 {#jah35215-sec-0008}

Transcatheter aortic valve replacement (TAVR) continues to revolutionize the treatment of severe, symptomatic aortic stenosis.[1](#jah35215-bib-0001){ref-type="ref"}, [2](#jah35215-bib-0002){ref-type="ref"} Patients with severe aortic stenosis undergoing TAVR frequently present with markers of right‐sided heart dysfunction, including pulmonary hypertension, tricuspid insufficiency, and right ventricular systolic dysfunction (RVSD). By conservative estimates, pulmonary hypertension is noted in at least 30% of patients undergoing TAVR, whereas the presence of moderate to severe tricuspid regurgitation (TR) has been estimated to be about 15% to 20%.[3](#jah35215-bib-0003){ref-type="ref"}, [4](#jah35215-bib-0004){ref-type="ref"} RVSD is also often underappreciated and has been estimated to occur in ≥24% of patients undergoing TAVR.[5](#jah35215-bib-0005){ref-type="ref"} There are a plethora of contributors to the development of RVSD, including left ventricular systolic dysfunction, myocardial ischemia secondary to coronary artery disease, and uncontrolled pulmonary arterial pressures.[4](#jah35215-bib-0004){ref-type="ref"}

Predictors of unfavorable outcomes after TAVR have been documented. They include oxygen‐dependent lung disease, renal dysfunction, poor functional capacity, and decreased baseline cognitive function.[6](#jah35215-bib-0006){ref-type="ref"}, [7](#jah35215-bib-0007){ref-type="ref"} Recent data suggest that even patients with advanced, severe left ventricular dysfunction who lack contractile reserve can tolerate TAVR reasonably well and may still garner some symptomatic benefit.[8](#jah35215-bib-0008){ref-type="ref"}, [9](#jah35215-bib-0009){ref-type="ref"}, [10](#jah35215-bib-0010){ref-type="ref"} But what about right ventricular (RV) systolic dysfunction? RVSD is considered to be a late marker of advanced heart failure. Currently, there are conflicting data on the impact of RVSD on clinical outcomes in patients with severe aortic stenosis treated with TAVR.[11](#jah35215-bib-0011){ref-type="ref"}, [12](#jah35215-bib-0012){ref-type="ref"}, [13](#jah35215-bib-0013){ref-type="ref"}, [14](#jah35215-bib-0014){ref-type="ref"}, [15](#jah35215-bib-0015){ref-type="ref"} A recent study indicated increased mortality post‐TAVR in patients with RVSD. However, that study did not use a standard definition of RVSD, relied on the highly variable echocardiography measures and cutoff values used by individual studies, and did not account for TR severity as an independent prognostic marker that can confound the association between RVSD and mortality.[16](#jah35215-bib-0016){ref-type="ref"} Given the conflicting data and lack of a consensus, we conducted a systematic review and meta‐analysis with a consolidated definition of RVSD (tricuspid annular plane systolic excursion \[TAPSE\] \<16, fractional area change \<35%, or decreased RV ejection fraction) to primarily analyze the impact of RVSD and, secondarily, the impact of TR and RV dilation on 1‐year mortality in patients with severe aortic stenosis undergoing TAVR.

Methods {#jah35215-sec-0009}
=======

The data that support the findings of this study are available from the corresponding author upon reasonable request. This systematic review was performed in accordance with the statement on Preferred Reporting Items for Systematic Reviews and Meta‐Analyses. A comprehensive systematic search was performed on July 1, 2017 that included PubMed, Embase, Cochrane Library, ACP Journal Club, DARE, and Scopus. Both controlled vocabulary terms (ie, Medical Subject Headings) and key words were used to obtain relevant articles. The aim was to identify randomized and nonrandomized clinical studies that focused on the prognosis and short‐term mortality of patients with severe symptomatic aortic stenosis who underwent TAVR. Emphasis was placed on studies that noted a history of RVSD, RV dilation, and TR. This study was exempt from institutional review board approval as no protected health information was included.

Key words utilized in the initial PubMed (NLM) MEDLINE title search were "aortic valve" or "transcatheter aortic" or "aortic" or "valve replacement" or "TAVR" or "implantation" and "right ventricular" or "right ventricle" or "right systolic" or "ventricular dysfunction" or "right failure" or "diastolic dysfunction."

Study Selection {#jah35215-sec-0010}
---------------

Articles were considered eligible if they assessed right ventricular systolic function (RVSF) using TAPSE, percent RV fractional area change, or RV ejection fraction in patients pre‐ and post‐TAVR with a minimum follow‐up of 12 months post‐TAVR. Our prespecified criteria were that studies were published between January 1, 2002 and July 1, 2017, as the first human TAVR was performed in 2002, and only studies involving human subjects and those written in English were included. Articles were excluded if the patients had congenital cardiomyopathy, significant pulmonary or mitral stenosis, atrial or ventricular septal defects, infective endocarditis, or perivalvular fistula formation. Case reports, abstracts, editorials, and commentaries were also excluded. Three independent reviewers (S.G., M.I., and G.S.) independently selected articles based on the predefined search criteria as well as quality assessment. Any disagreement or discrepancies were resolved by majority consensus. Reference lists from previous studies were also perused for additional articles to be appraised.

Echocardiogram and RVSF Assessment {#jah35215-sec-0011}
----------------------------------

Although guidelines for the assessment of RVSF in adults have been described elsewhere,[17](#jah35215-bib-0017){ref-type="ref"} there remains a fair degree of variability in the clinical, qualitative, and quantitative assessment of RVSF. Furthermore, many of these measures may not have been routinely collected in various registries and trials, which limits retrospective data analysis. In this meta‐analysis, we identified studies that performed quantitative appraisal of RVSF with transthoracic echocardiography to measure TAPSE, fractional area change, and/or RV ejection fraction at baseline as well as post‐TAVR.

Statistical Analysis {#jah35215-sec-0012}
--------------------

Hazard ratios (HRs) with 95% CIs were used to compare pooled data from the included studies and respective treatment effects for binary end points. Continuous variable outcomes were compared with weighted mean differences. Der Simonian and Laird random‐effects models were used due to the anticipated heterogeneity between studies.[11](#jah35215-bib-0011){ref-type="ref"}, [13](#jah35215-bib-0013){ref-type="ref"}, [14](#jah35215-bib-0014){ref-type="ref"}, [15](#jah35215-bib-0015){ref-type="ref"}, [18](#jah35215-bib-0018){ref-type="ref"}, [19](#jah35215-bib-0019){ref-type="ref"}, [20](#jah35215-bib-0020){ref-type="ref"}, [21](#jah35215-bib-0021){ref-type="ref"}, [22](#jah35215-bib-0022){ref-type="ref"} Heterogeneity was examined using the Cochran Q test and *I* ^2^ statistics. *P*\<0.10 and *I* ^2^\>5% were considered significant for heterogeneity.

Results {#jah35215-sec-0013}
=======

An initial search of collective databases produced 1476 articles, with 763 articles remaining after the removal of 713 duplicates. A total of 752 articles were further excluded due to their lack of relevance to the scope of our study. The remaining 11 articles were appraised for eligibility using our inclusion and exclusion criteria, after which 8 articles remained for final inclusion in our meta‐analysis (Figure [1](#jah35215-fig-0001){ref-type="fig"}). The remaining 8 articles were comprised of 2 randomized, controlled clinical trials and 6 observational studies. All of the 8 studies selected for our meta‐analysis evaluated RVSF using transthoracic echocardiography to assess TAPSE, RV fractional area change and/or RV ejection fraction, and magnetic resonance imaging at baseline as well as post‐TAVR.

![Flow diagram of Preferred Reporting Items for Systematic Reviews and Meta‐Analyses.\
Keywords title search used to identify PubMed (NLM) MEDLINE articles: ((aortic valve\[Title\] OR transcatheter aortic\[Title\] OR aortic\[Title\] OR valve replacement\[Title\] OR TAVR\[Title\] OR implantation\[Title\])) AND (right ventricular\[Title\] OR right ventricle\[Title\] OR right systolic\[Title\] OR ventricular dysfunction\[Title\] OR right failure\[Title\] OR diastolic dysfunction\[Title\]) Filters: Humans, English, From 2002/01/01 to 2017/07/01. Retrieved articles: 542.](JAH3-9-e014463-g001){#jah35215-fig-0001}

The studies included our meta‐analysis were chosen with the goal of evaluating outcomes in post‐TAVR patients with underlying RSVD, RV dilation, and/or TR, and compared with post‐TAVR patients with normal RV function. We defined our primary end point as the incidence of all‐cause mortality in patients with moderate to severe RVSD who underwent TAVR, with the secondary outcomes being the assessment of RV dilation or TR severity as a possible independent risk factor for 1‐year all‐cause mortality post‐TAVR.

The 8 selected studies were all single‐center studies published between 2007 and 2015, with an aggregate of 3166 patients across all studies. Mean age was 80.4±3.7 years. There was no difference in sex distribution. Baseline clinical and procedural characteristics are summarized in [Table](#jah35215-tbl-0001){ref-type="table"}. The overall incidence of RVSD was 37.49%.[8](#jah35215-bib-0008){ref-type="ref"}, [13](#jah35215-bib-0013){ref-type="ref"}, [14](#jah35215-bib-0014){ref-type="ref"}, [15](#jah35215-bib-0015){ref-type="ref"}, [16](#jah35215-bib-0016){ref-type="ref"}, [20](#jah35215-bib-0020){ref-type="ref"}, [23](#jah35215-bib-0023){ref-type="ref"} Cumulative 1‐year mortality of patients with and without RVSD was 40.52% and 29.40%, respectively. In 4 of the 8 studies included, the 3‐year mortality of patients with RVSD was found to be 9.88%, compared with 14.2% in patients without RVSD.[13](#jah35215-bib-0013){ref-type="ref"}, [14](#jah35215-bib-0014){ref-type="ref"}, [15](#jah35215-bib-0015){ref-type="ref"}, [23](#jah35215-bib-0023){ref-type="ref"}

###### 

Baseline Characteristics of Selected Studies Included in the Meta‐Analysis

<table><thead><tr class="header"><th>Author</th><th>Country, Year</th><th>Procedure</th><th>Type of Valve</th><th>Sample Size, n</th><th>Study Design</th><th>Male (%)</th><th>Age, y (Mean)</th><th>Mean STS Score (%)</th><th>RV Measurement (TAPSE, FAC, or S′)</th><th>Degree of TR</th><th>Pulmonary HTN</th><th>Duration</th></tr></thead><tbody><tr class="odd"><td>1. Ito et al<a href="#jah35215-bib-0015" data-ref-type="ref">15</a></td><td>USA, 2013</td><td>TF‐TAVR, TA‐TAVR</td><td>Sapiens XT</td><td>268</td><td>Prospective</td><td><p>50</p><p>72.1</p></td><td><p>80.5±8.1</p><p>80.1±7.6</p></td><td><p>9.5±4.8</p><p>10.8±5.6</p></td><td>No RV dilation: 200</td><td>TR in no RV dilation: 21</td><td>PASP in no RV dilation: 41.5±11.8</td><td>5 y</td></tr><tr class="even"><td>RV dilation: 68</td><td>TR in RV dilation: 31</td><td>PASP in RV dilation: 55.2±17.3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>2. Koifman et al<a href="#jah35215-bib-0016" data-ref-type="ref">16</a></td><td>USA, 2015</td><td>TAVR</td><td>CoreValve</td><td>606</td><td>Prospective</td><td><p>42</p><p>65</p></td><td><p>84±7</p><p>81±9</p></td><td><p>9.1±4.4</p><p>9.5±5.3</p></td><td>FAC &gt;0.35: 146</td><td>TR in no RV dilation, 19</td><td>PASP in RVSD: 50±17</td><td>1 y</td></tr><tr class="even"><td>FAC &lt;0.35: 460</td><td>TR in no RV dilation: 38</td><td>PASP in no RVSD: 44±16</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>3. Lindman et al<a href="#jah35215-bib-0020" data-ref-type="ref">20</a></td><td>USA, 2012</td><td>TAVR (from PARTNER II trial)</td><td>Sapiens, Sapiens XT</td><td>488</td><td>RCT</td><td><p>49</p><p>56</p></td><td><p>84±8</p><p>86±10</p></td><td><p>10.1±5.3</p><p>11.5±6.0</p></td><td>Normal S′ :68</td><td>No TR/mild TR: 372</td><td>PASP for mild MR: 27; moderate: 31</td><td>1 y</td></tr><tr class="even"><td>Abnormal S′: 50</td><td>Moderate TR: 117; severe TR: 18</td><td>Severe: 28</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>4. Poliocikovaet al<a href="#jah35215-bib-0023" data-ref-type="ref">23</a></td><td>UK, 2011</td><td>TF‐TAVR, TA‐AVR, TS‐TAVR</td><td>Medtronic</td><td>142</td><td>Prospective</td><td><p>61</p><p>48</p></td><td><p>79±4.7</p><p>82±6.3</p></td><td>Not reported</td><td>TAPSE &lt;15: 18</td><td>Mild TR: 97 (62.6%); moderate TR: 20 (12.9%)</td><td>Mean PAP for mild TR: 45 (29.0%)</td><td>4 y</td></tr><tr class="even"><td>TAPSE &gt;15: 124</td><td>Severe TR: 13 (8.4%)</td><td>Moderate TR: 15 (9.7%); severe TR: 14 (9%)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>5. Schwartz et al<a href="#jah35215-bib-0014" data-ref-type="ref">14</a></td><td>Israel, 2009</td><td>TAVR</td><td>Not reported</td><td>519</td><td>Prospective</td><td><p>43</p><p>46</p></td><td><p>82.4±6</p><p>84.8±5</p></td><td><p>Euroscore: 22.2±14</p><p>27.9±13</p></td><td>TAPSE in mild TR: 19.5±4</td><td><p>TR &lt; moderate: normal, 37; mild: 46; moderate: 16;</p><p>severe: 7</p></td><td>PASP in TR &lt; moderate: 39.4±13</td><td>3 y</td></tr><tr class="even"><td><p>TAPSE in moderate/severe</p><p>TR: 18.4±5</p></td><td><p>TR &gt; moderate: normal, 5; mild, 46;</p><p>moderate, 47; severe, 12</p></td><td>PASP in TR &gt; moderate: 61.2±13</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>6. Griese et al<a href="#jah35215-bib-0013" data-ref-type="ref">13</a></td><td>Germany, 2014</td><td>TF‐TAVR, TA‐TAVR</td><td>Sapiens XT, CoreValve</td><td>702</td><td>Prospective</td><td><p>39.3</p><p>60</p></td><td><p>80±2</p><p>82±5</p></td><td><p>Euroscore: 30±15</p><p>17.±12</p></td><td>TAPSE &gt;18: 462</td><td>Not reported</td><td>Not reported</td><td>5 y</td></tr><tr class="even"><td><p>TAPSE 14–18: 190;</p><p>TAPSE &lt;14: 50</p></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>7. Hutter et al<a href="#jah35215-bib-0005" data-ref-type="ref">5</a></td><td>Germany, 2014</td><td>TF‐TAVR, TA‐TAVR</td><td>Sapiens, CoreValve</td><td>251</td><td>Prospective</td><td><p>47.9</p><p>45.5</p></td><td><p>80.8±6.4</p><p>80.5±7.4</p></td><td><p>5.7±3.4</p><p>7.1±4.3</p></td><td>Normal RV: 161</td><td>Reported with MR</td><td>Mean PAP &gt;60 mm Hg: 62</td><td>1 y</td></tr><tr class="even"><td>RV dysfunction: 45</td><td></td><td>Mean PAP &gt;60 mm Hg: 206</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td>8. Lindsay et al<a href="#jah35215-bib-0021" data-ref-type="ref">21</a></td><td>UK, 2016</td><td>TF‐TAVR</td><td>Sapiens</td><td>190</td><td>Prospective</td><td><p>49</p><p>51</p></td><td><p>79.7</p><p>81.4</p></td><td>Not reported</td><td><p>Cardiac MRI</p><p>RVEF &gt;50: 145</p></td><td>Not reported</td><td>PASP RV &lt;50 mm Hg: 45</td><td>2 y</td></tr><tr class="even"><td><p>Cardiac MRI</p><p>RVEF &lt;50: 45</p></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>

HTN indicates hypertension; MR, mitral regurgitation; MRI, magnetic resonance imaging; NRV, normal right ventricular function; PAP, pulmonary artery pressure; PASP (mm Hg), pulmonary artery systolic pressure (mm Hg); RVD, right ventricular dilation; RVEF, right ventricular ejection fraction; RVSP, right ventricle systolic pressure; S′, tricuspid lateral annular systolic velocity; STS, Society of Thoracic Surgeons operative mortality risk score; TA‐TAVR, transapical transcatheter aortic valve replacement; TF‐TAVR, transfemoral transcatheter aortic valve replacement; TR, tricuspid regurgitation; and TS‐TAVR, transseptal transcatheter aortic valve replacement.

RVSD, as assessed with TAPSE, fractional area change, or ejection fraction, was found to be an independent predictor of adverse procedural outcome after TAVR (HR, 1.31; 95% CI, 1.1--1.55; *P*=0.002) (Figure [2](#jah35215-fig-0002){ref-type="fig"}). Overall, we found that RVSD did affect post‐TAVR prognosis in 1‐year mortality rate. In addition, the funnel plot revealed a similar outcomes distribution, thereby publication bias is unlikely (Figure [3](#jah35215-fig-0003){ref-type="fig"}).

![Forest plot evaluating the impact of normal right ventricle function on all‐cause mortality in 1‐year vs RV dysfunction.\
RV function is shown to be an independent predictor of adverse outcome after TAVR given the results did show a significant statistical difference (HR, 1.31; 95% CI, 1.10--1.55; *P*=0.002). HR indicates hazard ratio; TAVR, transcatheter aortic valve replacement; and RV, right ventricle.](JAH3-9-e014463-g002){#jah35215-fig-0002}

![Funnel plot showing no publication bias.](JAH3-9-e014463-g003){#jah35215-fig-0003}

Discussion {#jah35215-sec-0014}
==========

Although earlier studies showed variable results, the present meta‐analysis of published studies assessing the effect of preoperative RVSD on 1‐year all‐cause mortality post‐TAVR has shown a statistically significant association between baseline RV dysfunction and mortality. Like several earlier single‐center studies, the current data support the finding that RVSD is an independent risk factor in short‐term all‐cause mortality in post‐TAVR patients. Three earlier retrospective studies have noted that RVSD, determined by low TAPSE values (\<14 mm) on 2‐dimensional echocardiogram, is associated with increased short‐term all‐cause mortality in post‐TAVR patients. However, these particular studies were limited by their small sizes. Most included \<100 patients, and had a limited number of patients with varying degrees of RVSD.[11](#jah35215-bib-0011){ref-type="ref"}, [13](#jah35215-bib-0013){ref-type="ref"}, [15](#jah35215-bib-0015){ref-type="ref"}, [22](#jah35215-bib-0022){ref-type="ref"}, [23](#jah35215-bib-0023){ref-type="ref"} Although all of the included studies specifically assessed RV function, the measures of RV function assessed varied between studies. Hutter et al[3](#jah35215-bib-0003){ref-type="ref"} noted the presence of RV dysfunction but did not specifically assess the outcomes‐based RV function. In reviewing their published data, the 1‐year mortality outcomes demonstrate 18 deaths over 54 people with moderate to severe TR (a surrogate for RV dysfunction) compared with 41 deaths over 197 people without moderate to severe TR for an HR of 1.9. In their study, the presence of RV dysfunction was noted to correlate and was significantly higher in those with moderate to severe TR than in those with mild to moderate TR: 10% versus 60%, respectively. Therefore, although this is a limitation, we used presence of severe TR as a surrogate marker of RV dysfunction. Our meta‐analysis supports the finding that RV dysfunction at baseline is an adverse marker of early mortality and adverse outcomes in TAVR patients.

Similar to our findings, a recent publication from the Swiss TAVR registry demonstrated that RVSD at baseline was associated with a \>2‐fold increased risk of cardiovascular death at 1 year after TAVR. Furthermore, there was a gradient of risk according to recovery of RV dysfunction.[24](#jah35215-bib-0024){ref-type="ref"} It is important to note that RVSD cannot be analyzed in isolation. We must also take into account the company it keeps, namely TR and pulmonary hypertension, which often coexist. Multiple studies indicated that increased RV dilation and TR severity are independent predictors of post‐TAVR mortality.[14](#jah35215-bib-0014){ref-type="ref"}, [19](#jah35215-bib-0019){ref-type="ref"} Evaluation of the effects of TR severity and RV size in the inoperable cohort of the Placement of Aortic Trans‐Catheter Valves II trial indicated that both RV dilation and TR severity were independent risk factors for 1‐year mortality. After multivariable adjustment, there remained an increased risk of mortality in both severe TR (HR, 3.20; 95% CI, 1.50--6.82; *P*=0.003) and moderate TR (HR, 1.60; 95% CI, 1.02--2.52; *P*=0.042).[19](#jah35215-bib-0019){ref-type="ref"} Increased RV dilation remained borderline significant after adjustment for TR severity (*P*=0.058). Increased RV dilation may correlate with the chronicity and severity of RV pressure or volume overload rather than RV function, although further information is needed. When adjusted for confounders, RVSD alone was not predictive of overall mortality post‐TAVR.[4](#jah35215-bib-0004){ref-type="ref"}, [14](#jah35215-bib-0014){ref-type="ref"}, [19](#jah35215-bib-0019){ref-type="ref"}

Historically, the presence of RVSD has been demonstrated to increase mortality in post--surgical aortic valve replacement patients.[25](#jah35215-bib-0025){ref-type="ref"}, [26](#jah35215-bib-0026){ref-type="ref"} Consequently, RVSD is considered an independent predictor of perioperative complications as well as late mortality after surgical aortic valve replacement.[26](#jah35215-bib-0026){ref-type="ref"}, [27](#jah35215-bib-0027){ref-type="ref"} The increased mortality may be multifactorial, including inadequate cardioprotection, high risk of right coronary air embolism, prolonged open heart surgery times, loss of atrioventricular synchrony, and reperfusion lung injury increasing pulmonary artery pressures.[27](#jah35215-bib-0027){ref-type="ref"} Each of these factors may contribute to the noncompensatory RV function secondary to postsurgical stress. However, these acute stressors cannot necessarily be extrapolated to post‐TAVR patients. TAVR is a minimally invasive procedure and therefore reduces the amount of stress on the heart and decreases the risk of postprocedure RVSD. Nonetheless, the presence of severe RVSD accompanied by TR may lead to poor outcomes in post‐TAVR patients.

During appraisal of data from the Placement of Aortic Trans‐Catheter Valves II trial, there was increased 1‐year mortality in patients with worsening TR: 16.9% for those with no or trace TR; 17.2% for mild TR; 32.6% for moderate TR; and 61.1% for severe TR (*P*\<0.001).[13](#jah35215-bib-0013){ref-type="ref"}, [19](#jah35215-bib-0019){ref-type="ref"} The current data coincide with the fact that RVSD is an independent risk factor of poor outcomes post‐TAVR; the associations between TR as well as RV dilation and poor outcomes emphasize the importance of right heart assessment in preoperative work‐up. TAVR remains the preferred intervention for patients with severe, symptomatic aortic stenosis with RVSD. In addition, improved outcomes in 1‐year mortality may result from initial assessment of RV function and optimization.[17](#jah35215-bib-0017){ref-type="ref"} Perhaps no single quantitative measure of RVSD alone is sufficient for the assessment of right‐sided heart function in patients undergoing TAVR. Instead, a multimodal model incorporating various measures as well as the assessment of pulmonary hypertension and TR would be better predictive of outcomes and likelihood of functional recovery after TAVR. The ideal measures of RVSD for assessment in the TAVR population remain unknown. The first step would be to decide which measures carry some prognostic importance and are easily reproducible. Although some of these earlier studies were conducted in high‐risk or inoperable patients, it will also be important to identify whether the predictive validity remains in patients at lower risk as well. Thereafter, perhaps future predictive models can begin incorporating RVSD into estimates of post‐TAVR outcomes as well as likelihood of recovery of function.

Limitations {#jah35215-sec-0015}
-----------

Our systematic review and meta‐analysis was limited by the availability of information and pertinent studies including data on RVSD in post‐TAVR assessment of all‐cause mortality. Our analysis is based on published and not patient‐level data, as we did not have available the patient‐level data for the included studies. In addition, as previously mentioned, there was significant heterogeneity in the methods of assessment of RVSF. Given there is no current "gold standard," and the definition of RVSD was not uniform throughout the studies, the included studies used different measures of RV function. Furthermore, as noted earlier, for the Hutter et al study[3](#jah35215-bib-0003){ref-type="ref"} we used a surrogate marker of RV dysfunction, namely severe TR. There was limited follow‐up assessment of RVSD for determination of recovery of function. Most studies included retrospective analyses of RV function post‐TAVR, which may have introduced bias in the presentation of the results.

Conclusions {#jah35215-sec-0016}
===========

Patients with severe, symptomatic aortic stenosis and concomitant RVSD have worse 1‐year post‐TAVR prognosis compared with those without RVSD. RV dilation and severe TR were associated with increased 1‐year morality post‐TAVR and should be considered as independent risk factors.[13](#jah35215-bib-0013){ref-type="ref"} Given the significant heterogeneity of effects, RVSD in isolation should not be used to exclude patients from consideration for TAVR. Further evaluation of long‐term morbidity and mortality as well as sustained improvement in functional class and symptoms will be required to better elucidate the prognostic value of baseline RVSD in patients undergoing TAVR.
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